Abstract
No public abstract is available from the verified source records.
Tahseer Khan, Syeda Batool Tirmizi, Reena Kumari, Omar Naeem, Abida Bukhari, Ayesha Ali Qureshi, Usman Khan, Muhammad Irfan Jamil
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
No local reference links have been materialized yet.
No local citing links have been materialized yet.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
10.1016/j.jhep.2023.06.003 · 2023
EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1016/j.jhep.2024.04.031 · 2024
Metabolic dysfunction-associated steatotic liver disease in adults: a review
10.1001/jama.2025.19615 · 2026
Skeletal muscle alterations in metabolic dysfunction-associated steatotic liver disease: a critical review of diagnostic, mechanistic, and therapeutic intersections
10.3748/wjg.v31.i31.110481 · 2025
The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
10.1016/j.clnu.2024.07.006 · 2024
Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis
10.1016/j.cgh.2023.02.013 · 2023
Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study
10.1038/s41387-023-00250-6 · 2023
Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression
10.1016/j.cgh.2022.01.020 · 2023
crossref
Confidence 100%
openalex
Confidence 95%
datacite
Confidence 0%
Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States
10.1186/s12937-025-01081-0 · 2025
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
10.1016/j.jhep.2016.12.022 · 2017
EASL clinical practice guidelines for the management of patients with decompensated cirrhosis
10.1016/j.jhep.2018.03.024 · 2018
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
10.1016/j.kint.2023.10.018 · 2024
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines
10.1161/cir.0000000000001063 · 2022
Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease
10.1111/liv.14719 · 2021
Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment
10.1016/j.jamda.2019.12.012 · 2020
SARC-F: a simple questionnaire to rapidly diagnose sarcopenia
10.1016/j.jamda.2013.05.018 · 2013
Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease
10.1002/jcsm.12754 · 2021
The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations
10.1186/s12876-024-03192-0 · 2024
The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population
10.1002/jcsm.13099 · 2022
MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: a nationwide study
10.1111/jgh.16261 · 2023
Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease
10.1016/j.cgh.2021.12.043 · 2023
Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease
10.1016/j.jhepr.2020.100171 · 2020
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
10.1016/j.jhep.2016.08.019 · 2017
Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction-associated fatty liver disease
10.1002/jcsm.13351 · 2023
Risk stratification for sarcopenic obesity in subjects with nonalcoholic fatty liver disease
10.1016/j.cgh.2022.11.031 · 2023
No additional external references are available.